Form 4: Adaptive Biotechnologies Executive Sells Shares to Cover Tax Obligations After RSU Vesting
SEC Form 4 Filing
Sharon Benzeno, Chief Commercial Officer of Adaptive Biotechnologies, sold shares to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).
Summary
- Sharon Benzeno, Chief Commercial Officer of Adaptive Biotechnologies, reported transactions involving the company's common stock and stock options.
- On March 4, 2025, Benzeno acquired 109,973 shares of common stock at $0 and was granted options to purchase 165,027 shares at an exercise price of $8.12, expiring on March 4, 2035.
- On March 5, 2025, Benzeno sold 41,600 shares at $6.98 and 3,065 shares at $6.99 to cover tax withholding obligations related to RSU vesting.
- Following these transactions, Benzeno directly owns 392,723 shares of common stock and options to purchase 165,027 shares.
- The stock options vest in installments, starting with 1/4 on March 4, 2026, and then 1/48 monthly thereafter.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The transactions are related to tax obligations and standard equity compensation practices, not necessarily indicative of a positive or negative outlook.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies. Sales to cover tax obligations upon vesting of equity awards are typical and don't necessarily indicate a negative outlook on the company.
Comparison to Industry Standards
- Executive compensation packages often include stock options and restricted stock units (RSUs) to align management's interests with those of shareholders.
- The vesting schedules and terms of these equity awards are generally comparable to those offered by other companies in the biotechnology industry.
- Companies like Illumina, Inc. and Thermo Fisher Scientific also utilize similar equity compensation strategies for their executives.
Stakeholder Impact
- The sale of shares by an executive could have a minor, temporary impact on the stock price, but is unlikely to have a significant long-term effect.
- The transactions do not directly impact employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 03/04/2025 | Acquisition of 109,973 common stock shares and grant of options to purchase 165,027 shares. |
| 03/05/2025 | Sale of 41,600 and 3,065 common stock shares to cover tax obligations. |
| 03/06/2025 | Date of Form 4 filing. |
| 03/04/2035 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.